Harold Bernstein Sells 16,142 Maze Therapeutics Shares at $27.61 Each

Harold Bernstein, Maze Therapeutics' R&D President and Chief Medical Officer (CMO), sold 16,142 shares of the company at $27.61 per share, totaling $445,620, as reported in a Form 4 filed with the Securities and Exchange Commission (SEC) on August 16, 2026.

Who is Harold Bernstein and What is His Real Role at Maze Therapeutics?

Harold Bernstein is a key leader at Maze Therapeutics, holding the positions of R&D President and CMO. In this role, he is responsible for the strategic direction and implementation of the company's research and development activities, as well as overseeing the medical aspects related to the company's products and services. This position grants him access to privileged information about the company's projects, clinical trial results, and future developments, which could significantly impact the value of Maze Therapeutics' shares.

As part of the leadership team, Harold Bernstein actively participates in strategic decisions regarding the direction of research, development of new products, and potential partnerships. His deep knowledge of the company's internal activities provides him with a clearer view of the company's financial health and future growth.

This level of access to information and influence over company decisions makes Harold Bernstein an insider whose transactions in Maze Therapeutics' shares are closely monitored by investors and analysts. The movements of these insiders can be considered potential indicators of the company's health and long-term prospects.

Transaction Details: 16,142 shares at $27.61 each

The transaction reported by Harold Bernstein involves the sale of 16,142 Maze Therapeutics shares at a price of $27.61 per share. It is important to distinguish between the per-share price ($27.61) and the total value of the transaction ($445,620). The number of shares sold and the price per share provide insights into Bernstein's confidence in the company's short-term prospects and the decisions he makes as a manager of his own investment portfolio.

The transaction date, August 16, 2026, is also a crucial element, as it situates the event within the context of market conditions and company news at that time. Investors examine these details to assess whether the transaction could be linked to recent company announcements, sector changes, or macroeconomic factors.

Why Insiders Sell Their Shares – Possible Reasons

There are several reasons why insiders like Harold Bernstein might sell shares of their own companies. One of the most common reasons is portfolio diversification. Insiders often have a significant portion of their wealth tied up in their company's shares, exposing them to high risk if the company's performance declines. Selling a portion of their shares can be a strategy to reduce this risk and diversify their investments.

Another reason could be tax planning. Insiders may sell shares to meet tax obligations, such as paying capital gains taxes or funding other personal expenses. In some cases, selling shares may also be a way for insiders to generate liquidity for personal uses, such as purchasing real estate or financing personal ventures.